Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 15.5703
- Book/Share 7.0657
- PB 4.4897
- Debt/Equity 0.0
- CurrentRatio 0.8673
- ROIC 0.1136
- MktCap 66656743301.7706
- FreeCF/Share 2.2968
- PFCF 14.2856
- PE 19.4003
- Debt/Assets 0.0
- DivYield 0.0375
- ROE 0.2418
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
Here's Why GSK (GSK) is a Strong Value Stock
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
Published: October 10, 2025 by: Seeking Alpha
Sentiment: Positive
GSK plc aka GlaxoSmithKline is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved market sentiment, with growth led by Specialty Medicines and geographic expansion in Europe. Unlike peers, GSK faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher valuation multiples.
Read More
GSK's Hidden Growth Engines Beyond HIV And Oncology
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Positive
GSK continues to successfully develop its oncology franchise. So, sales of its "gem" in the treatment of myelofibrosis, called Ojjaara, reached $183 million in the second quarter of 2025, increasing by 71% year-on-year. In addition, GSK increased its 2025 sales growth outlook from a "low-double digit percentage" to a "low-teens percentage."
Read More
Why GSK (GSK) is a Top Growth Stock for the Long-Term
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
GSK plc (NYSE:GSK ) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDT Company Participants Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Sachin Jain - BofA Securities, Research Division Presentation Sachin Jain BofA Securities, Research Division Sachin Jain here from the European team, Bank of America. It's my pleasure to be hosting Glaxo.
Read More
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
Read More
GSK commits $30bn to US drug research and manufacturing
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) will pour $30 billion into research, development and manufacturing in the United States over the next five years, in one of the largest overseas investment programmes announced by a UK-listed company. The commitment includes a fresh $1.2 billion package unveiled today to expand production capacity and adopt artificial intelligence and digital technologies across its American operations.
Read More
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
Published: September 17, 2025 by: CNBC
Sentiment: Positive
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
Read More
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
Published: September 16, 2025 by: WSJ
Sentiment: Positive
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
Read More
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.
Read More
GSK Adds Around $5B in a Month: Here's How to Play the Stock
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
Published: August 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
GSK opens higher after priority review for new gonorrhoea pill
Published: August 11, 2025 by: Proactive Investors
Sentiment: Positive
Shares in GSK PLC (LSE:GSK, NYSE:GSK) opened higher following the US Food and Drug Administration's acceptance of gepotidacin for priority review as an oral treatment for uncomplicated urogenital gonorrhoea. The decision, based on positive phase III data from the EAGLE-1 trial, sets a target FDA decision date of December 2025.
Read More
GSK's antibiotic drug gepotidacin gets priority review by FDA
Published: August 11, 2025 by: Reuters
Sentiment: Positive
British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral treatment of uncomplicated urogenital gonorrhoea.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
Read More
GSK may have numbers may have been flattered by order timing, says bank
Published: July 30, 2025 by: Proactive Investors
Sentiment: Neutral
GSK PLC (LSE:GSK, NYSE:GSK) delivered a strong set of second-quarter results, beating expectations on sales, profits, and earnings per share, and raised its guidance to the top end of its previous range. However, UBS analysts caution that much of this outperformance was driven by timing effects, such as early HIV medicine orders and stock builds, particularly in France for the Shingrix vaccine, which are likely to reverse later in the year.
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Emma Natasha Walmsley
- Employees 68629